These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: An open label study of the effects of rituximab in neuromyelitis optica.
    Author: Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C.
    Journal: Neurology; 2005 Apr 12; 64(7):1270-2. PubMed ID: 15824362.
    Abstract:
    Eight patients with worsening neuromyelitis optica were treated with rituximab to achieve B cell depletion. Treatment was well tolerated. Six of eight patients were relapse free and median attack rate declined from 2.6 attacks/patient/year to 0 attacks/patient/year (p = 0.0078). Seven of eight patients experienced substantial recovery of neurologic function over 1 year of average follow-up. The pretreatment median Expanded Disability Status Scale score was 7.5, and at follow-up examination was 5.5 (p = 0.013).
    [Abstract] [Full Text] [Related] [New Search]